CK1α-dependent activation of these pathways could be therefore usefully targeted in a therapeutic perspective and the design of novel inhibitors of CK1α would be suitable for a use in the clinical setting to overcome MCL therapy resistance. The gene discussed is CSNK1A1; the disease is mantle cell lymphoma.